Pim-1 Kinase As Cancer Drug Target: An Update

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2016 Feb 20

PMID 26893828

Citations 51

Authors

Yernar Tursynbay

Jinfu Zhang

Zhi Li

Tursonjan Tokay

Zhaxybay Zhumadilov

Denglong Wu

Yingqiu Xie

Affiliations

Soon will be listed here.

Abstract

Proviral integration site for Moloney murine leukemia virus-1 (Pim-1) is a serine/threonine kinase that regulates multiple cellular functions such as cell cycle, cell survival, drug resistance. Aberrant elevation of Pim-1 kinase is associated with numerous types of cancer. Two distinct isoforms of Pim-1 (Pim-1S and Pim-1L) show distinct cellular functions. Pim-1S predominately localizes to the nucleus and Pim-1L localizes to plasma membrane for drug resistance. Recent studies show that mitochondrial Pim-1 maintains mitochondrial integrity. Pim-1 is emerging as a cancer drug target, particularly in prostate cancer. Recently the potent new functions of Pim-1 in immunotherapy, senescence bypass, metastasis and epigenetic dynamics have been found. The aim of the present updated review is to provide brief information regarding networks of Pim-1 kinase and focus on its recent advances as a novel drug target.

Citing Articles

: Pharmacological potential revealed by phytochemical and in silico investigations.

Naji Bin-Asal F, Saeed A, Alawi Bin Yahia A Biochem Biophys Rep. 2025; 41:101940.

PMID: 39995632 PMC: 11848803. DOI: 10.1016/j.bbrep.2025.101940.

Investigational drugs in early phase trials for myelofibrosis.

Arora S, Vachhani P, Bose P Expert Opin Investig Drugs. 2024; 33(12):1231-1244.

PMID: 39604120 PMC: 11669310. DOI: 10.1080/13543784.2024.2434696.

Effect of hinokitiol in ameliorating oral cancer: in vitro and in silico evidences.

Roy A, Cheriyan B, Perumal E, Rengasamy K, Anandakumar S Odontology. 2024; .

PMID: 39540968 DOI: 10.1007/s10266-024-01020-1.

Design, synthesis, and anti-breast cancer activity evaluation of novel 3-cyanopyridine derivatives as PIM-1 inhibitors.

Hussein B, Mohammed H, Ahmed E, Alshazly O, Mohamed M, Omran O Mol Divers. 2024; .

PMID: 39521748 DOI: 10.1007/s11030-024-11010-8.

PIM-1L Kinase Binds to and Inactivates SRPK1: A Biochemical and Molecular Dynamics Study.

Lesgidou N, Koukiali A, Nikolakaki E, Giannakouros T, Vlassi M Proteins. 2024; 93(3):629-653.

PMID: 39462863 PMC: 11809128. DOI: 10.1002/prot.26757.

References

Lilly M, Sandholm J, Cooper J, Koskinen P, Kraft A . The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999; 18(27):4022-31. DOI: 10.1038/sj.onc.1202741. View

Gribar J, Ramachandra M, Hrycyna C, Dey S, Ambudkar S . Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol. 2000; 173(3):203-14. DOI: 10.1007/s002320001020. View

Dhanasekaran S, Barrette T, Ghosh D, Shah R, Varambally S, Kurachi K . Delineation of prognostic biomarkers in prostate cancer. Nature. 2001; 412(6849):822-6. DOI: 10.1038/35090585. View

Aho T, Sandholm J, Peltola K, Mankonen H, Lilly M, Koskinen P . Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004; 571(1-3):43-9. DOI: 10.1016/j.febslet.2004.06.050. View

Jiang T, Guo Z, Dai B, Kang M, Ann D, Kung H . Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem. 2004; 279(48):50181-9. DOI: 10.1074/jbc.M409108200. View

Kim K, Baird K, Ahn J, Meltzer P, Lilly M, Levis M . Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2004; 105(4):1759-67. DOI: 10.1182/blood-2004-05-2006. View

Stout B, Bates M, Liu L, Farrington N, Bertics P . IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils. J Immunol. 2004; 173(10):6409-17. DOI: 10.4049/jimmunol.173.10.6409. View

Bachmann M, Moroy T . The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005; 37(4):726-30. DOI: 10.1016/j.biocel.2004.11.005. View

Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J . Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol. 2005; 348(1):183-93. DOI: 10.1016/j.jmb.2005.02.039. View

10.

Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H . The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 2005; 25(1):70-8. DOI: 10.1038/sj.onc.1209058. View

11.

Holder S, Lilly M, Brown M . Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem. 2007; 15(19):6463-73. DOI: 10.1016/j.bmc.2007.06.025. View

12.

Zippo A, De Robertis A, Serafini R, Oliviero S . PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 2007; 9(8):932-44. DOI: 10.1038/ncb1618. View

13.

Zhang Y, Wang Z, Magnuson N . Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res. 2007; 5(9):909-22. DOI: 10.1158/1541-7786.MCR-06-0388. View

14.

Xie Y, Xu K, Linn D, Yang X, Guo Z, Shimelis H . The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2007; 283(6):3349-3356. DOI: 10.1074/jbc.M707773200. View

15.

Saris C, Domen J, Berns A . The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991; 10(3):655-64. PMC: 452698. DOI: 10.1002/j.1460-2075.1991.tb07994.x. View

16.

Hogan C, Hutchison C, Marcar L, Milne D, Saville M, Goodlad J . Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem. 2008; 283(26):18012-23. PMC: 2695321. DOI: 10.1074/jbc.M709695200. View

17.

Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N . Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008; 68(13):5076-85. DOI: 10.1158/0008-5472.CAN-08-0634. View

18.

Tong Y, Stewart K, Thomas S, Przytulinska M, Johnson E, Klinghofer V . Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett. 2008; 18(19):5206-8. DOI: 10.1016/j.bmcl.2008.08.079. View

19.

Hu X, Li J, Vandervalk S, Wang Z, Magnuson N, Xing P . PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest. 2009; 119(2):362-75. PMC: 2631288. DOI: 10.1172/JCI33216. View

20.

Schmidt-Arras D, Bohmer S, Koch S, Muller J, Blei L, Cornils H . Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood. 2009; 113(15):3568-76. DOI: 10.1182/blood-2007-10-121426. View